The published evidence
What the numbers show — and which question each one answers.
7 in 10
Men treated for a painful varicocele whose pain resolved, or eased enough that they
were satisfied — at a median follow-up of 44.5 months, in a series of 182 procedures.²
This is the pain number. Not a six-month result.
1.5 days
Off work after embolization, against 6.8 days after microsurgery, in the one prospective
study that measured both. Post-procedure pain was lower too — 22% vs 44% of men with
more than mild pain.³
96%
Technical success — the vein successfully closed — across 225 men in a
15-year, two-center series, with a complication rate of 1.78%.¹ This is the
plumbing number, not the pain number. Different question, different figure.
6 in 100
Varicoceles confirmed back on ultrasound, at an average of about 34 months.¹ And among
men whose varicocele reappeared on ultrasound, only about 1 in 6 had their pain come
back.² We treat the man, not the scan.
2,138 men
Pooled across 16 studies comparing the catheter route with surgery head-to-head.
Recurrence and pregnancy rates came out statistically indistinguishable
— for embolization specifically, RR 0.90 and RR 1.02.⁵ The 76-man study
behind the recovery figure is one of those sixteen, not a separate finding.
A third fewer
Adverse events after the catheter route than after surgery, in that same pooled
analysis — RR 0.63.⁵ Read it as the route, not as us: it counts embolization and
sclerotherapy together, and the surgery it’s measured against is a mix of open,
laparoscopic and microsurgical repair.
What the numbers don’t say: 96% describes whether the vein closed
— 7 in 10 is the pain figure, and roughly 3 in 10 men did not get the relief they came for.
Complications counted more inclusively run higher than 1.78% — 10.45% in the pain series,
all self-limited, most commonly a small tear in the vein during the procedure (about 3%) that
settles on its own.² Both numbers are honest; they count differently, and we’d rather
show you both than pick the flattering one.
Where the pooled comparisons land. Two analyses have pooled the studies
comparing the catheter route with surgery, and they disagree about recurrence: the 2022 one,
16 studies and 2,138 men, found no difference between the routes;⁵ a larger 2025 analysis
of 30 studies found varicoceles came back modestly more often after the catheter route
— odds ratio 1.37.⁶ They agree on the other half. Both found fewer complications
after the catheter route, and the 2025 one found far less of the fluid collection around the
testicle that surgery sometimes causes.⁶ Two things neither one settles: pain,
which no study has ever measured with both treatments side by side in the same men —
which is why you won’t see surgery’s pain numbers printed next to ours — and
microsurgery specifically, which neither pool isolates; the surgery counted in them is a mix of
surgical routes. Microsurgical repair still has the lowest recurrence rate of any route, and
it’s the one to ask a surgeon for.
Sources: 1. de Grae MNM, Al-khattab M, Alkadhimi A, Springael M, O’Sullivan G. A
fifteen-year retrospective analysis of varicocele embolization: evaluating success, recurrence rates and
embolic agents. CVIR Endovasc 2025;8:59 — 225 patients, two centers, 2008–2023; technical
success 96%; clinical success 93.75%; ultrasound-confirmed recurrence 6.25% at 34 ± 17.7 months;
complications 1.78%; indications pain 68%; no significant outcome difference between embolic agents.
2. Haroun P, Murgo S, Mjaess G, et al. Percutaneous embolization for painful varicocele: an 8-year tertiary
centre experience. J Belg Soc Radiol 2025;109(1):2 — 182 procedures; technical success 88.15%;
clinical success for pain 70.42%; median follow-up 44.5 months; complications 10.45%, all self-limited;
pain recurrence in 17.24% of ultrasound recurrences. 3. Bou Nasr E, Binhazzaa M, Almont T, et al. Subinguinal
microsurgical varicocelectomy vs. percutaneous embolization in infertile men: prospective comparison of
reproductive and functional outcomes. Basic Clin Androl 2017;27:11 — 76 men (49 microsurgery,
27 embolization); spontaneous pregnancy 36.7% vs 33.3% (ns); sick leave 6.8 vs 1.5 days (p=0.002); pain
>2/5 in 44% vs 22% (p=0.007); complications 3 vs 0. 4. American Urological Association / American Society
for Reproductive Medicine. Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline (2020; amended
2024) — recommendations paraphrased, not quoted; prevalence figures as cited there. 5. Liu Q, Zhang X,
Zhou F, Xi X, Lian S, Lian Q. Comparing endovascular and surgical treatments for varicocele: a systematic
review and meta-analysis. J Vasc Interv Radiol 2022;33(7):834–840 — 16 studies,
2,138 patients; recurrence RR 1.03 (95% CI 0.78–1.36); pregnancy RR 1.03 (0.85–1.25); adverse
events RR 0.63 (0.42–0.93, P=.02); embolization subgroups recurrence RR 0.90 (0.55–1.47) and
pregnancy RR 1.02 (0.79–1.30); adverse events not reported separately for embolization; semen
parameters not analyzed; comparator surgery a mix of open, laparoscopic and microsurgical repair.
6. Chen H, Liu K, Liu M, Jin T, Zhou L. Comparison of sclero-embolization and surgical ligation for
varicocele treatment: a systematic review and meta-analysis. World J Urol 2025;43 —
30 studies; recurrence OR 1.37 (1.03–1.82); overall complications OR 0.65 (0.47–0.91);
hydrocele OR 0.19 (0.10–0.35). 7. Owen RC, McCormick
BJ, Figler BD, Coward RM. A review of varicocele repair for pain. Transl Androl Urol
2017;6(Suppl 1):S20–S29. 8. Park JH, Pak K, Park NC, Park HJ. How can we predict a successful outcome
after varicocelectomy in painful varicocele patients? An updated meta-analysis. World J Mens Health
2021;39(4):645–653.